Adma Biologics, Inc. (ADMA) Stock Price & Analysis
Adma Biologics, Inc. (ADMA) rose 0.74% to USD 8.12 as of June 10, 2026 at 08:31 UTC, according to Nexqual real-time market data.
ADMA last closed at USD 8.06; the session ranged USD 8.02–8.3 on volume of 3,012,576 shares. Market capitalization is $1.88B, with a 52-week range of USD 7.21–22.37 (NGM). Source: Nexqual, June 10, 2026 at 08:31 UTC.
Key Statistics (as of June 10, 2026 at 08:31 UTC)
| Price | USD 8.12 |
|---|---|
| Change | ▲ 0.74% (up) |
| Previous Close | USD 8.06 |
| Open | USD 8.09 |
| Day Range | USD 8.02 – 8.3 |
| 52-Week Range | USD 7.21 – 22.37 |
| Volume | 3,012,576 shares |
| Market Cap | $1.88B |
| Exchange | NGM |
Technical Analysis (ADMA)
Nexqual's technical model rates ADMA "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:31 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.62 (neutral) |
| vs SMA50 | Below (USD 9.31) |
| MACD | -0.53 (negative) |
Analyst Ratings (ADMA)
Wall Street analysts rate ADMA "None" based on 4 analysts, with a mean price target of USD 16.75 (range USD 12–20), per Nexqual as of June 10, 2026 at 08:31 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 16.75 |
| High Target | USD 20 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (ADMA)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.18 |
| Revenue Estimate | $134.43M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.17 vs est 0.2 ▼ miss |
| 2025-12-31 | USD 0.22 vs est 0.2 ▲ beat |
| 2025-09-30 | USD 0.16 vs est 0.16 ▲ beat |
| 2025-06-30 | USD 0.15 vs est 0.14 ▲ beat |
Source: Nexqual, June 10, 2026 at 08:31 UTC.
Financials & Fundamentals (ADMA)
| Total Revenue | $509.86M |
|---|---|
| Revenue Growth (YoY) | +15.90% |
| Gross Margin | +61.27% |
| Operating Margin | -123.39% |
| Profit Margin | +32.43% |
| ROE | +43.30% |
| Debt / Equity | 110.67 |
| Current Ratio | 6.95 |
| Total Cash | $55.92B |
| Total Debt | $97.67B |
| Free Cash Flow | $58.35M |
Source: Nexqual, June 10, 2026 at 08:31 UTC.
Financial Health Score (ADMA)
Nexqual rates Adma Biologics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 08:31 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $55.9B cash vs $97.7B debt |
| Cash Flow | Solid — FCF $58M, 11% margin |
| Efficiency | Strong — ROE 43%, ROA 22.0% |
Ownership (ADMA)
| Insider Ownership | +1.87% |
|---|---|
| Institutional Ownership | +93.95% |
| Shares Outstanding | 231.77M |
| Float | 226.73M |
| Short % of Float | +10.50% |
Source: Nexqual, June 10, 2026 at 08:31 UTC.
Leadership (ADMA)
Adma Biologics, Inc. is led by Adam S. Grossman (age 48), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 08:31 UTC.
| Co-Founder, President, CEO & Director | Adam S. Grossman (age 48) |
|---|---|
| Co-Founder & Vice Chairman of the Board | Jerrold B. Grossman D.P.S. (age 77) |
| CFO & Treasurer | P. Terence Kohler |
| COO & Senior VP of Compliance | Kaitlin M. Kestenberg (age 38) |
| Executive Director of Sales | John Hafl |
Major Backers & Investors (ADMA)
Notable institutional backers of Adma Biologics, Inc. include Capital Group, SmallCap World Fund Inc, American Century Companies Inc, according to Nexqual as of June 10, 2026 at 08:31 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 4.83% |
| SmallCap World Fund Inc | 4.44% |
| American Century Companies Inc | 3.52% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 3.35% |
| Citadel | 2.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 24.5% |
| Vanguard Group | 13.67% |
| State Street | 8.45% |
| Nuveen | 2.63% |
| Geode Capital | 2.51% |
Source: Nexqual, June 10, 2026 at 08:31 UTC.
From Adma Biologics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- The end-to-end production cycle can take approximately seven to 12 months for a batch of FDA released drug product.
- We anticipate submitting a pre-Investigational New Drug (IND) package to the FDA in fiscal year 2026, which could enable us to progress development of SG-001 directly into a registrational clinical trial.
- As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to respiratory syncytial virus ("RSV") using our proprietary microneutralization testing assay.
- Utilizing our intellectual property patents, which include our proprietary testing assay and other standardization methods and technologies, we have identified potential new product candidates that we may advance into preclinical activities.
Partnerships
- Effective October 1, 2024, we entered into an Amended and Restated Plasma Purchase Agreement with Grifols (the "A&R Grifols Agreement") with a term expiring in September 2039, after which it may be renewed for two additional multi-year periods if agreed to by the parties.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABUS | Arbutus Biopharma Corporation | USD 4.25 | ▲ 0% |
| ARDX | Ardelyx, Inc. | USD 5.6 | ▲ 0.72% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
| XERS | Xeris Biopharma Holdings, Inc. | USD 6.5 | ▲ 5.18% |
| ABEO | Abeona Therapeutics Inc. | USD 5.45 | ▼ 0.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:31 UTC. This page is informational and not investment advice.